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Abstract: A number of 7-alkyl 4-aminopyrrolo[2,3-glpyrimidine derivatives related to toyocamycin, 
sangivamycin and thiosangivamycin have been prepared and tested for their activity against human 
cytomegalovirus (HCMV). Only the thioamide substituted derivatives demonstrated biological activity. 
Human cytomegalovirus (HCMV) infection is relatively benign in healthy individuals but can be 
debilitating or fatal to immunosuppressed individuals such as transplant recipients’ and AIDS patients.2 The 
drugs currently approved for the treatment of HCMV are ganciclovir (GCV, DHPG)3 and foscarnet (PFA).4 
The clinical use of these compounds is limited because of host toxicity. s-6 In addition, there have been recent 
report@ that strains of HCMV resistant to both drugs are emerging. Hence, there is a continued need to 
develop compounds which may circumvent the problems associated with the use of DHPG and PFA to treat 
HCMV infections. 
The naturally occurring pyrrolo[2,3-d]pyrimidine nucleosides toyocamycin (I), sangivamycin (2) and a 
structurally related analog, thiosangivamycin (3), possess significant activity against HCMVg-lo 
I 
1: RI = CN, R2 = O-D-Rbofuranose 2: R, = CONH2, R2 = RD-Ribofuranose 
3. RI = CSNH2, R2 = R-II-Ribofuranose 4: R1 = CSNH2, R2 = CH20CH&H20H 
but are highly toxic to mammalian cells. - 9 12 Both toyocamycin and sangivamycin are phosphorylated by 
celfular adenosine kinase which ul~mately leads to their toxicity in uninfested cells.13 In previous studies of 
sugar modified analogs of 1,2 and 3,tr-l2.14-rs t i was reported that acyclic analogs of 3 possesssed good activity 
against HCMV coupled with a significant reduction in cytotoxicity;lr, 14-rs e.g., 4-amino-7-[(2- 
* Portions of this study were presented at the 204th American Chemical Society National Meeting 
(Medi # 1811, August 1992, Washington D. C. 
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hydroxyethoxy)methyl]pyrrolo[2,3-~]pyrimidine-5-thiocarboxamide (4).14mt5 Interestingly, similar acyclic 
analogs of 1 and 2 were also non-toxic but inactive against HCMV. 11, i* This suggested that the structural 
requirements of the substitutent at N-7 (R2) may have less importance than the thioamide moiety at C-5 (RI) for 
the acyclic thiosangivamycin analogs to have activity against HCMV. If this is indeed the case, one might 
expect that a side chain hydroxyl group may not be essential for biological activity. In fact, recent studies have 
established that certain non-nucleoside analogs do have antiviral activity. 19-21 To test our hypothesis, we have 
prepared several analogs of toyocamycin. sangivamycin and thiosangivamycin where the substituents at N-7 
cannot be phosphorylated. In the present report, we describe the synthesis, antiviral activity and cytotoxicity of 
a number of model compounds. 
Scheme I illustrates the synthetic route we used to prepare the non-nucleoside analogsz2 Compounds 7a 
and 7b were prepared m a similar manner to that reported for 4 14 from 2-amino-5-bromo-3,4-dicyanopyrrole 
(5)23 in yields of 20 and 30%, respectively. Treatment of Sz3 with triethylorthoformate followed by the addition 

















b. R = CH2CH&H2 C R = CH2CH2CH3 
1) CH(OEt)s, CHsCN; 2) NaH, RX, CHsCN; ii. NH3/MeOH; 
HP, PcVC, EtOAc/EtOH orZn/AcOH (see text); iv NH40H/H20/EtOH, H202, 
MeOH, Hg3NaOMe 
reacted directly with methanolic ammonia to afford the ‘I-substituted 4-amino-6-bromopyrrolo[2,3+ 
pyrimidine-5carbonitriles (7a-b). The toyocamycin analogs 8a and 8c were obtained in 50-70% yields from 7a 
and 7b, respectively, viu catalytic hydrogenation while a selective reduction of 7b in zinc and acetic acid 
afforded 4-amino-7-~allyl)pyrrolo[2,3-~]pyrimidine-5-carboninile (Sb) in a yield of 75%. The carboxamides 
(9a-c) were synthesized from the appropriate compound 8 in 7590% using 30% hydrogen peroxide in aqueous 
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Table I: Antiviral activity and cytotoxicity of several 5,7disubstituted 4-aminopyrrolo[2,3-d-pyrimidines. 
NH2 R, 
N’ 3r, L I ’ N N 
I 
f32 
Compound Substituent 50% Inhibitory Concentrations 
(uM) 



















































0.19 f 0.2 
8.8 + 5.8 
6.2 f 5.1 
1.2 fi 0.8 
2.1 f 1.9 

















14.7 f 6.0 
19.0 f 2.8 







aResults are the mean of three or more experiments + SD. bunless otherwise noted, cytotoxicity tests were 
performed in KB cells as described in Ref. 24. c”>” indicates 1C50 concentration not reached at highest 
concentration tested. dRef. 11. Tytotoxicity determined in L1210 cells. kef. 15. gVisua1 cytotoxicity in 
HFF cells. hRef. 14. iAverage of > 50 experiments. SI: selectivity index-CC5flC5o. 
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base, and the thiosangivamycin analogs (10 a-c) were also prepared from the appropriate nitrile (8) in 
methanolic sodium sulfide in a sealed vessel at 95” C in 80-9.5% yields. 
Compounds 8a-c, 9a-c and IOa-c were evaluated for activity against HCMV by a plaque reduction 
assay9 in human foreskin fibroblasts (HFF cells), and the cytotoxicity of each compound in uninfected cells was 
determined by examining the effects on the growth of KB cells. 24 The results are presented in Table I. 
Antiviral and cytoxicity data for the ribosyl, hydroxyethoxymethyl and dihydroxypropoxymethyl substituted 
pyrrolopyrimidines are presented for comparison. The data confirm that the major factor required for the 
antiviral activity of these 7-substituted 4-aminopyrrolo-[2,3_d]pyrimidines is the thioamide moiety at the 5- 
position (Rl), and that the hydroxyl group of 3 or 4 1s not necessarily required for the compound to have activity 
against HCMV. As with the acyclic analogs, It,15 the non-nucleoside analogs of toyocamycin (Sax) and 
sangivamycm (9a-c) were non-toxic and relatively inactive against HCMV. In general, the thioamides were 
more toxic than the carboxamides which, in turn, were more toxic than the corresponding nitriles. Although the 
potency of compounds lOa-c against HCMV is greater than that of 4, the toxicity in uninfected cells also was 
greater. Therefore, the selectivity index for analogs lOa-c remain essentially the same when compared to that of 
the parent compound 4 (therapeutic ratios of 9-14 vs 13, respectively). The separation of cytotoxicity from 
antiviral activity, though, is greater for compounds lOa-c when compared to that of thiosangivamycm (3), 
tndicating viral selectivity. 
In summary, the design, synthesis and antiviral evaluation of several non-nucleoside pyrrolo- 
[2,3-8]pyrimidines was examined. This study was initiated to investigate the possibility that a side chain 
hydroxyl group of analogs with known activity against HCMV, such as compounds 3 or 4, may not be required 
for biological activity. The data herein suggest that the thioamide moiety provides antiviral activity without the 
requirement for phosphorylation of a side chain hydroxyl group. Since the activity of these compounds is 
mediated via a unique mechanism, biological studies to elucidate the mechanism of action are underway. We 
are expanding our studies with this class of compounds by making several selective alkyl and aryl substitutions 
at the 7-position of the base as well as examining modifications at other sites on the heterocycle with the initial 
goal of increasing the therapeutic index. 
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